The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1449
ISSUE1449
August 18, 2014
Sucroferric Oxyhydroxide (Velphoro) for Hyperphosphatemia
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Sucroferric Oxyhydroxide (Velphoro) for Hyperphosphatemia
August 18, 2014 (Issue: 1449)
Most patients with end-stage renal disease develop
hyperphosphatemia, which can lead to secondary hyperparathyroidism,
vascular calcification, and cardiovascular
mortality. The FDA has approved sucroferric oxyhydroxide
(Velphoro – Fresenius...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.